Modig Berndt sold $90K of PHVS

Modig Berndt (Chief Executive Officer) sold 2,291 shares of Pharvaris N.V. (PHVS) at $39.40 on 2026-09-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Modig Berndt
Published Sep 15, 2026, 6:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 6:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$PHVS
Neutral
medium confidence
Mentioned
$PHVS
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PHVSNeutralLow
01

Why it matters

The CEO's sale via a pre‑arranged plan is a routine liquidity move; unlikely to drive major price change.

02

Market read

Provides fresh insider data for traders monitoring PHVS; limited broader market effect.

03

What to watch

Potential upcoming clinical data or financing events not disclosed.

Relevance 2/10Novelty 5/10Timing: post‑market 2026‑09‑14

Background

Form 4 filing reveals insider transaction for Pharvaris N.V. (PHVS).

Company-level read

Ticker impact

$PHVSNeutralMedium confidence
Context

CEO Modig Berndt sold 2,291 shares for $90,276 via a 10b5‑1 plan.

Expected impact

Potential short‑term downward pressure, likely limited to a few cents.

Evidence & confidence

The sale size is modest relative to holdings; market may view it as routine.

Market effects

Minimal impact on biotech sector; typical insider activity.

No significant regional effect.

Limited to investors tracking PHVS.

Counterpoint

The sale could be a strategic tax‑loss harvest rather than a negative signal.

Key entities

  • Pharvaris N.V.

    Biotech firm listed on Nasdaq under ticker PHVS.

  • Modig Berndt

    Chief Executive Officer of Pharvaris.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$PHVSMed

Pharvaris reports Q3 results

Pharvaris reported a Q3 EPS of -$0.67, with cash reserves of €283M as of September 30, 2026, down from €292M at year-end 2025. The company's net loss widened to €47.4M, up from €37.1M year-over-year. Recently, Pharvaris presented at healthcare conferences and announced positive late-stage trial results for its hereditary angioedema drug, leading to an upgrade by BofA to 'Buy'.

$PHVSMedAI 8/10

Pharvaris (PHVS) Reports Q3 Results After Phase 3 Milestone

Pharvaris (PHVS) reported Q3 2026 results, highlighting FDA review of deucrictibant IR NDA with a 2027 PDUFA date. Phase 3 study data for deucrictibant XR expected in 1Q2027. NDA submission for deucrictibant XR in AE-BK attacks planned for 1H2027. Cash position of €283M as of Q3 2026. No financial figures provided for Q3.